PL54 injection safety in adults with PKU

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label Phase 1 trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PL54 in adults with PKU. It has two parts: Phase Ia tests single subcutaneous doses across five weight-based groups, followed by a 2-week screening and 4-week safety follow-up; Phase Ib tests four weekly injections with ongoing safety monitoring and ADA/PK analyses. Dose escalation to new groups depends on safety data and a Safety Monitoring Committee decision. About 30 subjects are planned for Phase Ia and around 18 for Phase Ib, enrolled at The First Affiliated Hospital of Anhui Medical University in China. The study will assess how body weight influences dose and how repeated dosing affects safety and immune responses.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Adult patients aged 18 to 55 years, inclusive, regardless of sex.
* Subjects with a prior diagnosis of phenylketonuria (PKU) meeting the following criteria:

  * Blood Phe concentration ≥600 µmol/L at screening;
  * Average blood Phe concentration ≥600 μmol/L within the 12 months prior to screening (with at least two test results available);
  * Genetic test report confirming the presence of phenylalanine hydroxylase (PAH) gene defects.
* Ability to maintain dietary stability from 3 days prior to screening through the end of the trial.
* Subjects (including partners) capable of practicing effective contraception during the trial period, with no plans for conception within 3 months after trial completion.
* Voluntarily sign the informed consent form and, in the investigator's judgment, able to comply with all study requirements.

Key Exclusion Criteria:

* Known hypersensitivity to PL54 injection or any of its excipients.
* Medical conditions or history assessed by the investigator that may increase the risk of severe allergic reactions (e.g., acute exacerbation of allergic asthma, atopic constitution, history of anaphylaxis, etc.).
* Use of any medication for PKU (including large neutral amino acids) within 14 days prior to study drug administration or within 5 half-lives of the drug (whichever is longer).
* Use or planned use of any injectable medication containing polyethylene glycol (PEG) (except the investigational drug) within 3 months prior to screening or during the study period, including medroxyprogesterone acetate injection.
* Prior use of Pegvaliase (PALYNZIQ®).
* History of any of the following manifestations associated with prior PEG-containing product use: systemic symptoms (e.g., respiratory or gastrointestinal symptoms, hypotension, angioedema, allergic reactions). The investigator will determine eligibility based on the severity of previous symptoms.
* Clinically significant abnormal vital signs, physical examination, laboratory tests, or other relevant findings at screening, deemed by the investigator to render the subject unsuitable for enrollment.
* Significant medical history of immunological, cardiovascular, respiratory, gastrointestinal, endocrine, renal, hematological, neurological, psychiatric, or malignant diseases (except basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been excised with no evidence of recurrence) assessed by the investigator prior to screening.
* Stable use of immunosuppressants (e.g., cyclosporine, azathioprine) within 4 weeks prior to screening, with inability to discontinue use during the study period.
* Vaccination within 4 weeks prior to screening or planned vaccination during the study period.
* Positive serology for Treponema pallidum-specific antibodies, human immunodeficiency virus (HIV) antibodies, hepatitis C virus (HCV) antibodies, or hepatitis B virus (HBV) surface antigen.
* Serum creatinine ratio \> 1.5 × upper limit of normal (ULN).
* Alanine aminotransferase (ALT) \> 2 × ULN.
* Pregnant or breastfeeding women.
* Participation in any investigational drug trial and receipt of an investigational product within 3 months prior to screening.
* Prior use of any gene therapy for phenylketonuria (including participation in clinical studies).
* Any other condition deemed by the investigator to preclude participation in the trial.

Where it's running

• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Jing Sun
• Email: sunj@pegbiocq.com
• Phone: 86-13983367811

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How often to check phenylalanine in adults with classic PKU

  This study tests whether checking phenylalanine levels weekly instead of monthly helps adults with classic PKU keep their levels under better control.

  Recruiting Jagiellonian University · Krakow · NCT07825883

• MZE782 in adults with phenylketonuria (PKU) testing safety and efficacy

  This study tests whether MZE782 works safely for adults with PKU compared with a placebo.

  Recruiting at 9 sites Phase 2 Maze Therapeutics · Oakland, California and 8 other locations · NCT07694440

• Multiomics (genome plus metabolome) approach for adults with phenylketonuria

  This project will test whether combining whole-genome sequencing from saliva and non-targeted blood metabolomics can find genetic and metabolic patterns linked to symptoms in adults who were treated for phenylketonuria from birth.

  Recruiting University Hospital, Tours · Angers and 14 other locations · NCT07484945

• Investigating brain aging in adults with phenylketonuria

  This study looks at how living with phenylketonuria (PKU) affects brain aging and thinking skills in adults who have followed a special diet since they were babies.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06969209

• Long-term JNT-517 treatment for people with phenylketonuria

  This trial tests the long-term safety of JNT-517 in children and adults with PKU, including people who previously took JNT-517 and those who are new to the drug.

  Recruiting at 12 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Gainesville, Florida and 11 other locations · NCT06628128

• Long-term evaluation of immune response in PKU patients receiving Palynziq

  This study is testing how well Palynziq works over 10 years for people with PKU by looking at their immune responses and overall health.

  Recruiting at 11 sites BioMarin Pharmaceutical · Aurora, Colorado and 10 other locations · NCT06305234

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.